A Randomized, Open-Label, 3-Period, Single-Dose, Cross-Over Study in Healthy Participants to Assess the Relative Bioavailability of AGMB-129 Given as Tablet Formulation Versus the Capsule Reference Formulation and to Assess the Effect of Food on Tablet Formulation
Latest Information Update: 21 May 2024
At a glance
- Drugs AGMB 129 (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- 15 May 2024 Status changed from active, no longer recruiting to completed.
- 07 May 2024 New trial record